Comparative Pharmacology
Head-to-head clinical analysis: CAPREOMYCIN SULFATE versus PASER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPREOMYCIN SULFATE versus PASER.
CAPREOMYCIN SULFATE vs PASER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting translation initiation. Also alters membrane permeability.
Inhibits cell wall synthesis in Mycobacterium tuberculosis by blocking mycolic acid synthesis. Also acts as a competitive inhibitor of folate synthesis.
15 mg/kg (up to 1 g) intramuscularly or intravenously once daily for 60 days, then 15 mg/kg (up to 1 g) 2-3 times weekly for 12-18 months in combination with other antituberculosis agents.
4 g (8 capsules of 500 mg) orally every 8 hours, taken with food or an acidic beverage (e.g., orange juice) to enhance absorption.
None Documented
None Documented
Terminal elimination half-life: 24-40 hours (prolonged in renal impairment; anuria may extend to 96-120 hours).
Terminal elimination half-life is 1.5 to 2.5 hours in patients with normal renal function. In anuria or severe renal impairment (CrCl <10 mL/min), half-life may extend to 8-12 hours. Clinical context: Accumulation occurs with renal failure, requiring dose adjustment.
Primarily renal (80-90% as unchanged drug via glomerular filtration). Biliary/fecal elimination: <1%.
Renal excretion accounts for approximately 80% of the administered dose, with about 60-70% as unchanged drug and 10-20% as metabolites (primarily acetylated). The remainder is excreted via feces (approximately 10-15%) and minor biliary elimination. Renal clearance is highly dependent on glomerular filtration rate.
Category C
Category C
Antitubercular Agent
Antitubercular Agent